Literature DB >> 15847800

Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells.

Gøril Berntzen1, Elin Lunde, Morten Flobakk, Jan Terje Andersen, Vigdis Lauvrak, Inger Sandlie.   

Abstract

In studies of the relation between structure and function of proteins of the immune system, there is a continuous need for screening of a large number of protein variants. To optimise the yield following transient gene expression in small or medium culture volumes, several parameters were investigated. First, secretion levels of a soluble form of human Fcgamma receptor IIA (FcgammaRIIA) were measured after transfection of 293, 293E, 293T as well as COS-7 cell lines. The transgene was under cytomegalovirus (CMV) promoter control on the expression vector pcDNA3, which also contains an SV40 origin of replication (SV40 ori). All 293 cell lines secreted more protein than COS-7 cells. Introduction of the Epstein Barr virus (EBV) origin of replication (oriP) greatly increased the protein expression from the 293E cells, both the amount of protein produced per day and the duration of production. At best, 293E cells secreted fully functional protein for 3-4 weeks provided supernatant was harvested every 2-3 days followed by medium replacement. This method was then used for expression of soluble forms of human FcgammaRI, FcgammaRIIB, the human neonatal Fc receptor (FcRn), a T cell receptor (TCR)-immunoglobulin (Ig) fusion protein, and human IgG3. With an initial culture volume of 5 ml, the yield was approximately 200 microg for FcgammaRIIA, 1.5 microg for FcgammaRI, 5 microg for FcRn, 20 microg for FcgammaRIIB, 40 microg for the TCR-Ig fusion protein and 850 microg for IgG3. Culture expansion during the 3 weeks of culture further increased the yield. Protein yield was also improved by scaling up the initial volume. This approach can provide sufficient amounts of protein for screening experiments, and in the case of antibody, milligrams of recombinant protein for extensive structural analysis can be obtained from one single transient transfection. The approach should be of interest to laboratories that do not have access to a bioreactor but still have a requirement for reasonable amounts of protein to be produced in an easy and cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847800     DOI: 10.1016/j.jim.2005.01.002

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  25 in total

1.  Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Authors:  Algirdas Grevys; Malin Bern; Stian Foss; Diane Bryant Bratlie; Anders Moen; Kristin Støen Gunnarsen; Audun Aase; Terje Einar Michaelsen; Inger Sandlie; Jan Terje Andersen
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

Review 2.  Large-scale transfection of mammalian cells for the fast production of recombinant protein.

Authors:  Phuong Lan Pham; Amine Kamen; Yves Durocher
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

3.  Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.

Authors:  Migyeong Jo; Hyeong Sun Kwon; Kwang-Hoon Lee; Ji Chul Lee; Sang Taek Jung
Journal:  MAbs       Date:  2017-12-07       Impact factor: 5.857

4.  Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.

Authors:  Kine Marita Knudsen Sand; Bjørn Dalhus; Gregory J Christianson; Malin Bern; Stian Foss; Jason Cameron; Darrell Sleep; Magnar Bjørås; Derry C Roopenian; Inger Sandlie; Jan Terje Andersen
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

5.  Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Bjørn Dalhus; Kristin Støen Gunnarsen; Jason Cameron; Algirdas Grevys; Karen Bunting; Inger Sandlie; Jan Terje Andersen
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

6.  Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

Authors:  Jan Terje Andersen; Rikard Pehrson; Vladimir Tolmachev; Muluneh Bekele Daba; Lars Abrahmsén; Caroline Ekblad
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

7.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

8.  Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Authors:  Jan Terje Andersen; Jason Cameron; Andrew Plumridge; Leslie Evans; Darrell Sleep; Inger Sandlie
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

9.  Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation.

Authors:  Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2013-09-23       Impact factor: 5.422

10.  Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease.

Authors:  Lene Støkken Høydahl; Lisa Richter; Rahel Frick; Omri Snir; Kristin Støen Gunnarsen; Ole J B Landsverk; Rasmus Iversen; Jeliazko R Jeliazkov; Jeffrey J Gray; Elin Bergseng; Stian Foss; Shuo-Wang Qiao; Knut E A Lundin; Jørgen Jahnsen; Frode L Jahnsen; Inger Sandlie; Ludvig M Sollid; Geir Åge Løset
Journal:  Gastroenterology       Date:  2018-12-26       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.